Arysta LifeScience Limited announced the acquisition of the Goëmar group from BeCapital and Pechel Industries. Goëmar is based in Saint-Malo, France, and is a global manufacturer and supplier of biostimulation, biocontrol and innovative nutrition for plants, including Physio Activator and Natural Defense technologies.

This acquisition builds on Arysta LifeScience’s biosolutions platform, originally developed from the GBM (Grupo Bioquímico Mexicano) acquisition in 2007, along with their biocontrol portfolio, NPP (Natural Plant Protection), with globally recognized products such as Atonik, Biozyme and Carpovirusine.

The two companies have already been working together to cross-market their biosolutions offerings in Europe, in addition to several commercial partnerships in high-growth countries, including India and Mexico.

Goëmar brings to Arysta LifeScience over 40 years of research and technical expertise in biosolutions, with a broad portfolio of highly differentiated products, cutting-edge innovation, and an industry-leading commercial organization with complementary competencies and geographic reach.

“Arysta LifeScience’s objective is to strengthen its leadership position in biosolutions, while also maximizing the synergies with traditional crop protection solutions,” said Wayne Hewett, CEO of Arysta LifeScience. “The acquisition of Goëmar is a key pillar for Arysta LifeScience’s continued growth in the rapidly expanding biosolutions space, with an aligned vision and passion towards this market.”

“We are excited to join Arysta LifeScience and to continue to execute our vision toward Bioperformance leadership in agriculture,” added Jean-Pierre Princen, Goëmar chief executive officer.

“The complementary nature of the two enterprises will provide additional capabilities to continue the tremendous growth we have experienced over the recent years. In addition, the combined strength of the two portfolios in biostimulation and biocontrol establishes a leading global player in these dynamic and growing segments.”

Terms of the transaction were not disclosed.